刊物主题:Biomedicine Cancer Research Pharmacology and Toxicology Oncology
出版者:Springer Berlin / Heidelberg
ISSN:1432-0843
文摘
Purpose Docetaxel (TXT) is a unique chemotherapeutic agent that has been approved for treating various types of malignancies. TXT stabilizes microtubule assembly in cells and causes various dysfunctions of microtubule-dependent cellular events. Patients with advanced malignancies are beginning to receive TXT in combination with immunotherapy; however, the influence of TXT at clinically achievable serum concentrations (less than 10–6 M) on antigen presentation-related functions of human monocyte-derived dendritic cells (Mo-DCs) remains unclear.